Recent Company News

• 05:02 PM ET Jul 22, 2026
  

  StreetAccount Sector Summary - Healthcare Post-Market

• 08:49 PM ET Sep 06, 2026
  

  Molecular Partners transferred buy at Clear Street; prior rating was buy ($4.35, 0.00)

• 01:06 AM ET Aug 25, 2026
  

  Molecular Partners reports H1 EPS (CHF0.70) vs year-ago (CHF1.00) (CHF 3.53, 0.00)

• 08:48 AM ET Jul 22, 2026
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 11:35 PM ET Jul 21, 2026
  

  Leerink Partners assumes AKTS, CMPX, KURA, others

• 01:03 AM ET Jul 15, 2026
  

  Molecular Partners showcases Bispecific Radio-DARPins at Gordon Research Conf (CHF 3.16, 0.00)

• 01:10 AM ET Jul 06, 2026
  

  Molecular Partners updates on clinical progress across DARPin Radiotherapeutics pipeline; new target nomination in H2 of 2026, with two INDs planned in 2027 (CHF 3.18, 0.00)

• 01:06 AM ET Jul 02, 2026
  

  Molecular Partners and Orano Med announce first patients dosed in Phase 1/2a trial of DLL3 Radio-DARPin MP0712 (CHF 3.10, 0.00)

• 12:09 PM ET May 27, 2026
  

  Transcript Intelligence: Molecular Partners at TD Cowen Oncology Innovation Summit